RAF1 and melanoma: Belvarafenib (HM95573) is a pan-RAF dimerization inhibitor that demonstrates selective anticancer activity with either cobimetinib or cetuximab in preclinical models, as well as in cancer patients with RAS or RAF mutations, especially melanoma patients (Table 1).